A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women

Trial Profile

A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs ADXS Dual (Primary) ; Nivolumab (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Advaxis; Bristol-Myers Squibb
  • Most Recent Events

    • 13 Jun 2017 According to an Advaxis media release, this study has been previewed at annual Investor & Analyst Day.
    • 02 Jun 2017 New trial record
    • 31 May 2017 According to an Advaxis media release, the company this study is expected to start by the end of year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top